Measures and Markers in Amyotrophic Lateral Sclerosis

NeuroRx

Volumn 1, Issue 2, 2004, Pages 273-283

  Cudkowicz, Merit ^a   Qureshi, Muhammad ^a   Shefner, Jeremy ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

ALS; ALSFRS; motor unit number estimate; outcome measures

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MARKER; HUMAN; NEUROANATOMY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL; SYMPTOM; ELECTRODIAGNOSIS; MAGNETISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW;

BIOLOGICAL MARKER;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; ELECTRODIAGNOSIS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETICS;

EID: 4644220635     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.1.2.273     Document Type: Article

References (142)

1. Mulder D. Clinical limits of amyotrophic lateral sclerosis. In: Rowland L. (Ed). Human motor neuron diseases (1982), Raven, New York 15-22
2. Kurtzke J., and Kurland L. The epidemiology of neurologic disease. In: Joynt R. (Ed). Clinical neurology (1989), J.B. Lippincot, Philadelphia 1-43
3. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of Riluzole in amyotrophic lateral sclerosis. N Engl J Med 330 (1994) 585-591
4. Lacomblez L., Bensimon G., Leigh P., Guillett P., and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347 (1996) 1425-1431
5. Rosen D., Siddique T., Patterson D., Figlewicz D., Sapp P., Hentati A., et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
6. Mitsumoto H. Diagnosis and progression of ALS. Neurology 48 (1997) S2-S8
7. Rowland L. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 160 Suppl (1998) 6-24
8. Brooks B. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124 (1994) 96-107
9. Kent-Braun J., Walker C., and Weiner M. Upper and lower motor neuron function and muscle weakness in amyotrophic lateral sclerosis. Neurology 46 (1996) A472
10. Chan S., Sungu D., Douglas-Akinwande A., Lange D., and Rowland L. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 212 (1999) 763-769
11. Ellis C., Simmons A., Jones D., Bland J., Dawson J., Horsfield M., et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 53 (1999) 1051-1058
12. Pioro E., Antel J., Cashman N., and Arnold D. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 44 (1994) 1933-1938
13. Suhy J., Schuff N., Maudslley A., Weiner M., and Miller R. Detection of ALS by proton magnetic resonance imaging. Neurology 54 (2000) A254-A255
14. Suhy J., Miller R., Rule R., Schuff N., Licht J., Dronsky V., et al. Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1) H MRSI. Neurology 58 (2002) 773-779
15. Sach M., Winkler G., Glauche V., Liepert J., Heimbach B., Koch M., Buchel C., and Weiller C. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 127 (2004) 340-350
16. Gurney M., Pu H., Chiu A., Dal Canto M., Polchow C., Alexander D., et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
17. Hayward L., Rodriguez J., Kim J., Tiwari A., Goto J., Cabelli D., et al. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial ALS. J Biol Chem (2002) 15923-I5931
18. Pasinelli P., Borchelt D., Houseweart M., Cleveland D., and Brown R. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 95 (1998) 15763-15768
19. Pasinelli P., Houseweart M., Brown R., and Cleveland D. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu/Zn superoxide dismutase mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 97 (2000) 13901-13906
20. Cleveland D., and Rothstein J. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2 (2001) 806-819
21. Yang Y., Hentati A., Deng H., Dabbagh O., Sasaki T., Hirano M., et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29 (2001) 160-165
22. Hadano S., Hand C., Osuga H., Yanagisawa Y., Otomo A., Devon R., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 29 (2001) 166-173
23. Puls I., Jonnakuty C., LaMonte B., Holzbaur E., Tokito M., Mann E., et al. Mutant dynactin in motor neuron disease. Nat Genet 33 (2003) 455-456
24. Zhao C., Takita J., Tanaka Y., Setou M., Nakagawa T., Takeda S., et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bβ. Cell 105 (2001) 587-597
25. Siddique T., Hong S., Brooks B., Hung W., Siddique N., Rimmler J., et al. X-linked dominant locus for late-onset familial amyotrophic lateral sclerosis. Am J Hum Genet (1998) A308
26. Hand C., Khoris J., and Salachas T. A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. Am J Hum Genet 70 (2002) 251-256
27. Chance P., Rabin B., Ryan S., Ding Y., Scavina M., Crain B., et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 62 (1998) 633-640
28. Andres P., Hedlund W., Finison L., Conlon T., Felmus M., and Munsat T. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 36 (1986) 937-941
29. Andres P., Thibodeau L., Finison L., and Munsat T. Quantitative assessment of neuromuscular deficit in ALS. Neurol Clin 5 (1987) 125-141
30. Munsat T., Andres P., Finison L., Conlon T., and Thibodeau L. The natural history of motorneuron loss in amyotrophic lateral sclerosis. Neurology 38 (1988) 409-413
31. Miller R., Petajan J., Bryan W., Armon C., Barohn R., Goodpasture J., et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 39 (1996) 256-260
32. Miller R., Moore D., Young L., and Western ALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 47 (1996) 1383-1388
33. Cudkowicz M., Shefner J., Schoenfeld D., Brown R., Johnson H., Qureshi M., et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61 (2003) 456-464
34. Miller R., Moore D., Gelinas D., Dronsky B., Mendoza M., Barohn R., et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 56 (2001) 843-848
35. Hoagland R., Mendoza M., Armon C., Barohn R., Bryan W., Goodpasture J., et al. Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with keamyotrophic lateral sclerosis. Syntex/Synergen Neuroscience Joint Venture rhCNTF ALS Study Group. Muscle Nerve 20 (1997) 691-695
36. Andres P., Hedlund W., Finison L., Conlon T., Felmus M., and Munsat T. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 36 (1986) 937-941
37. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurology 46 (1996) 1244-1249
38. Smith R., Melmed S., Sherman B., Fane J., Munsat T., and Festoff B. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 16 (1993) 624-633
39. Stambler N., Charatran M., Cedarbaum J., et al. Prognostic indicators of survival in ALS. Neurology 50 (1998) 66-72
40. Pestronk A., Lopate G., Kornberg A., Elliott J., Blume G., Yee W., et al. Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology 44 (1994) 2027-2031
41. Schneider-Gold C., Beck M., Wessig C., George A., Kele H., Reiners K., et al. Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy. Neurology 60 (2003) 500-502
42. Drachman D., Chaudhry V., Cornblath D., Kuncl R., Pestronk A., Clawson L., et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 35 (1994) 142-150
43. Beck M., Giess R., Wurffel W., et al. Comparison of maximal voluntary isometric contraction and Drachman's hand-held dynamometry in evaluating patients with amyotrophic lateral sclerosis. Muscle Nerve 22 (1999) 1265-1270
44. Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 61 (2003) 1503-1506
45. Ziter F., Allsop K., and Tyler F. Assessment of muscle strength in Duchenne muscular dystrophy. Neurology 27 (1977) 981-984
46. Florence J., Pandya S., King W., Robison J., Signore L., Wentzell M., et al. Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures. Phys Ther 64 (1984) 41-45
47. Brooks B., Sufit R., DePaul R., Tan Y., Sanjak M., and Robbins J. Design of clinical therapeutic trials in amyotrophic lateral. In: Rowland L. (Ed). Amyotrophic lateral sclerosis and other motor neuron disease (1991), Raven, New York
48. Lyall R., Polkey M., Leigh P., and Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 124 (2001) 2000-2013
49. Varrato J., Siderowf A., Damiano P., Gregory S., Feinberg D., and McCluskey L. Postural change of forced vital capacity predicts some respiratory symptoms in ALS. Neurology 57 (2001) 357-359
50. Magnus T., Beck M., Giess R., Puls I., Naumann M., and Toyka K. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 25 (2002) 709-714
51. Black L., and Hyatt R. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 99 (1969) 696-702
52. Appel V., Stewart S., Smith G., and Appel S. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 22 (1987) 328-333
53. Haverkamp L., Appel V., and Appel S. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118 (1995) 707-719
54. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The amyotrophic lateral sclerosis functional rating scale. Arch Neurol 53 (1996) 141-147
55. Cedarbaum J. The amyotrophic lateral sclerosis functional rating scale (ALSFRS). Arch Neurol 53 (1996) 141-147
56. Cedarbaum J., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169 (1999) 13-21
57. Clarke S., Hickey A., O'Boyle C., and Hardiman O. Assessing individual quality of life in amyotrophic lateral sclerosis (2001) 149-158
58. Cruveilhier J. Sur la paralysie musculaire progressive atrophique. Arch Gen Med 91 (1853) 561-603
59. Charcot J., and Joffroy A. Deux cas d'atrophie musculaire progressive ave lesions de la substance grise et des faisceaux anterolateraux de la moelle epineire. Arch Physiol 2 (1869) 354-367
60. Piao Y., Wakabayashi K., Kakita A., Yamada M., Hayashi S., Morita T., et al. Neuropathology with clinical correlations of sporadic amyotrophic lateral sclerosis: 102 autopsy cases examined between 1962 and 2000. Brain Pathol 13 (2003) 10-22
61. Sasaki S., and Iwata M. Ultrastructural study of Betz cells in the primary motor cortex of the human brain. J Anat 199 (2001) 699-708
62. Tsuchiya K., Ikeda K., Mimura M., Takahashi M., Miyazaki H., Anno M., et al. Constant involvement of the Betz cells and pyramidal tract in amyotrophic lateral sclerosis with dementia: a clinicopathological study of eight autopsy cases. Acta Neuropathol (Berl) 104 (2002) 249-259
63. van Welsem M., Hogenhuis J., Meininger V., Metsaars W., Hauw J., and Seilhean D. The relationship between Bunina bodies, skein-like inclusions and neuronal loss in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 103 (2002) 583-589
64. Yaguchi M., Hashizume Y., Yoshida M., Gonatas N., and Okamoto K. Reduction of the size of the Golgi apparatus of spinal anterior horn cells in patients with X-linked spinal and bulbar muscular atrophy. Amyotroph Lateral Scler Other Motor Neuron Disord 4 (2003) 17-21
65. Fujita Y., Okamoto K., Sakurai A., Kusaka H., Aizawa H., Mihara B., et al. The Golgi apparatus is fragmented in spinal cord motor neurons of amyotrophic lateral sclerosis with basophilic inclusions. Acta Neuropathol (Berl) 103 (2002) 243-247
66. Dubowitz V., and Brooke M. Muscle biopsy: a practical approach (1985), Bailliere Tindall, London
67. Tsukagoshi H., Yanagisawa N., Oguchi K., Nagashima K., and Murakami T. Morphometric quantification of the cervical limb motor cells in controls and in amyotrophic lateral sclerosis. J Neurol Sci 41 (1979) 287-297
68. Shefner J. Motor unit number estimation in human neurological diseases and animal models. Clin Neurophysiol 112 (2001) 955-964
69. Shefner J., and Gooch C. Motor unit number estimation in neurologic disease. Adv Neurol 88 (2002) 33-52
70. Bromberg M., Forshew D., Nau K., Bromberg J., Simmons Z., and Fries T. Motor unit number estimation, isometric strength, and electromyographic measures in amyotrophic lateral sclerosis. Muscle Nerve 16 (1993) 1213-1219
71. Shefner J., and Gooch C. Motor unit number estimation. Phys Med Rehabil Clin N Am 14 (2003) 243-260
72. Bromberg M., and Larson W. Relationships between motor-unit number estimates and isometric strength in distal muscles in ALS/MND. J Neurol Sci 139 Suppl (1996) 38-42
73. Bromberg M., and Abrams J. Sources of error in the spike-triggered averaging method of motor unit number estimation (MUNE). Muscle Nerve 18 (1995) 1139-1146
74. Doherty T., Stashuk D., and Brown W. Determinants of mean motor unit size: impact on estimates of motor unit number. Muscle Nerve 16 (1993) 1326-1331
75. Lomen-Hoerth C., and Olney R. Comparison of multiple point and statistical motor unit number estimation. Muscle Nerve 23 (2000) 1525-1533
76. Armon C., and Brandstater M. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve 22 (1999) 1571-1575
77. Felice K. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve 20 (1997) 179-185
78. Yuen E., and Olney R. Longitudinal study of fiber density and motor unit number estimate in patients with amyotrophic lateral sclerosis. Neurology 49 (1997) 573-578
79. Daube J. Estimating the number of motor units in a muscle. J Clin Neurophysiol 12 (1995) 585-594
80. McComas A., Fawcett P., Campbell M., and Sica R. Electrophysiological estimation of the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry 34 (1971) 121-131
81. McComas A., Galea V., and de Bruin H. Motor unit populations in healthy and diseased muscles. Phys Ther 73 (1993) 868-877
82. McComas A., Quartly C., and Griggs R. Early and late losses of motor units after poliomyelitis. Brain 120 (1997) 1415-1421
83. Brown W. A method for estimating the number of motor units in thenar muscles and the changes in motor unit count with ageing. J Neurol Neurosurg Psychiatry 35 (1972) 845-852
84. Brown W. Thenar motor unit count estimates in the carpal tunnel syndrome. J Neurol Neurosurg Psychiatry 36 (1973) 194-198
85. Olney R., Yuen E., and Engstrom J. Statistical motor unit number estimation: reproducibility and sources of error in patients with amyotrophic lateral sclerosis. Muscle Nerve 23 (2000) 193-197
86. Shefner J., Jillapalli D., and Bradshaw D. Reducing intersubject variability in motor unit number estimation. Muscle Nerve 22 (1999) 1457-1460
87. Hansen S., and Ballantyne J. A quantitative electrophysiological study of motor neurone disease. J Neurol Neurosurg Psychiatry 41 (1978) 773-783
88. Carleton S., and Brown W. Changes in motor unit populations in motor neurone disease. J Neurol Neurosurg Psychiatry 42 (1979) 42-51
89. Dantes M., and McComas A. The extent and time course of motoneuron involvement in amyotrophic lateral sclerosis. Muscle Nerve 7 (1991) 416-421
90. Arasaki K., and Tamaki M. A loss of functional spinal alpha motor neurons in amyotrophic lateral sclerosis. Neurology 51 (1998) 603-605
91. Andres P., Thibodeau L., Finison L., and Munsat T. Quantitative assessment of neuromuscular deficit in ALS. Neurol Clin 5 (1987) 125-141
92. Andres P., Finison L., Conlon T., Thibodeau L., and Munsat T. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 38 (1988) 405-408
93. Olney R., Yuen E., and Engstrom J. The rate of change in motor unit number estimates predicts survival in patients with amyotrophic lateral sclerosis. Neurology 52 Suppl 2 (1999) A3
94. Armon C., and Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. J Neurol Sci 160 Suppl 1 (1998) S37-S41
95. Armon C., Graves M., Moses D., Forte D., Sepulveda L., Darby S., et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 23 (2000) 874-882
96. Shefner JM. Motor unit number estimation in a multicenter clinical trial. Paper presented at the 14th international symposium on ALS/MND, Milan, Italy, November, 2003.
97. Eisen A., and Swash M. Clinical neurophysiology of ALS. Clin Neurophysiol 112 (2001) 2190-2201
98. Urban P., Wicht S., and Hopf H. Sensitivity of transcranial magnetic stimulation of cortico-bulbar vs. cortico-spinal tract involvement in amyotrophic lateral sclerosis (ALS). J Neurol 248 (2001) 850-855
99. Hess C., Mills K., Murray N., and Schriefer T. Magnetic brain stimulation: central motor conduction studies in multiple sclerosis. Ann Neurol 22 (1987) 744-752
100. Mills K., and Nithi K. Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle Nerve 20 (1997) 1137-1141
101. Eisen A., Pant B., and Stewart H. Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. Can J Neurol Sci 20 (1993) 11-16
102. Ziemann U., Winter M., Reimers C., Reimers K., Tergau F., and Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 49 (1997) 1292-1298
103. Weber M., and Eisen A. Assessment of upper and lower motor neurons in Kennedy's disease: implications for corticomotoneuronal PSTH studies. Muscle Nerve 22 (1999) 299-306
104. Zanette G., Tamburin S., Manganotti P., Refatti N., Forgione A., and Rizzuto N. Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis. J Neurol 249 (2002) 1723-1728
105. Sarchielli P., Pelliccioli G., Tarducci R., Chiarini P., Presciutti O., Gobbi G., et al. Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 43 (2001) 189-197
106. Rooney W., Miller R., Gelinas D., Schuff N., Maudsley A., and Weiner M. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 50 (1998) 1800-1805
107. Pioro E. Proton magnetic resonance spectroscopy (1H-MRS) in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) S7-S16
108. Pioro E., Majors A., Mitsumoto H., Nelson D., and Ng T. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 53 (1999) 71-79
109. Pohl C., Block W., Karitzky J., Traber F., Schmidt S., Grothe C., et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol 58 (2001) 729-735
110. Kenn W., Ochs G., Pabst T., and Hahn D. 1H spectroscopy in patients with amyotrophic lateral sclerosis. J Neuroimaging 11 (2001) 293-297
111. Bowen B., and Bradley W. Amyotrophic lateral sclerosis: the search for a spectroscopic marker of upper motoneuron involvement. Arch Neurol 58 (2001) 714-716
112. Bowen B., Pattany P., Bradley W., Murdoch J., Rotta F., Younis A., et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 21 (2000) 647-658
113. Kalra S., Genge A., and Arnold D. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord 4 (2003) 22-26
114. Kalra S., Cashman N., Caramanos Z., Genge A., and Arnold D. Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am J Neuroradiol 24 (2003) 476-480
115. Vielhaber S., Kaufmann J., Kanowski M., Sailer M., Feistner H., Tempelmann C., et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol 172 (2001) 377-382
116. Groeneveld G., Veldink J., van der Tweel I., Kalmijn S., Beijer C., de Visser M., et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53 (2003) 437-445
117. Rothstein J., Tsai G., Kuncl R., et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28 (1990) 18-25
118. Camu W., Billiard M., and Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 88 (1993) 51-55
119. Bogdanov M., Brown R., Matson W., Hayden D., O'Donnell H., Beal F., et al. Increased oxidative damage to DNA in ALS patients. Free Radical Biology 29 (2000) 652-658
120. Beal M., Ferrante R., Browne S., Matthews R., Kowall N., and Brown R. Increased 3-Nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42 (1997) 644-654
121. Smith R., Henry Y., Mattson M., and Appel S. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44 (1998) 696-699
122. Simpson E., Henkel J., Henry Y., Smith R., and Appel S. Elevated levels of 4-HNE in the sera of patients with amyotrophic lateral sclerosis. Neurology 60 (2003) A242
123. Beuche W., Yushchenko M., Mader M., Maliszewska M., Felgenhauer K., and Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. NeuroReport 11 (2000) 3419-3422
124. Houi K., Kobayashi T., Kato S., Mochio S., and Inoue K. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 106 (2002) 299-301
125. Ranganathan S., Jordan K., Sathanoonri R., Henry S., Wood P., Urbinelli L., et al. Identification of ALS specific biomarkers by protein profiling of cerebral spinal fluid. Amyotroph Lateral Scler Other Motor Neuron Disord 4 (2003) 12
126. Bogdanov M., Rozen S., Kristall B., Matson W., Vigneau-Callahan K., Flarakos J., et al. Metabolic profiling and signatures in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 3 (2002) 26
127. Jackson M., Morrison K., al-Chalabi A., Bakker M., and Leigh P. Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: homozygous NAIP deletion in a sporadic case. Ann Neurol 39 (1996) 796-800
128. Parboosingh J., Meininger V., McKenna-Yasek D., Brown R., and Rouleau G. Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis. Arch Neurol 56 (1999) 710-712
129. Moulard B., Salachas F., and Chassande B. Association between centromeric deletions of the SMN gene and sporadic adult-onset lower motor neuron disease. Ann Neurol 43 (1998) 640-644
130. Corcia P., Mayeux-Portas V., and Khoris J. Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann Neurol 51 (2002) 243-246
131. Mui S., Rebeck G., McKenna-Yasek D., Hyman B., and Brown R. Apolipoprotein E E4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Ann Neurol 38 (1995) 460-463
132. Al-Chalabi A., Enayat Z., Bakker M., et al. Association of apolipoprotein E E4 allele with bulbar-onset motor neuron disease. Lancet 347 (1996) 159-160
133. Moulard B., Sefiani A., Laamri A., Malafosse A., and Camu W. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. J Neurol Sci 139 Suppl (1996) 34-137
134. Smith R., Haverkamp L., Case S., Appel S., and Appel V. Apolipoprotein E E4 in bulbar-onset motor neuron disease. Lancet 348 (1996) 334-335
135. Takahashi R. Deficiency of human ciliary neurotrophic factor (CNTF) is not causally related to amyotrophic lateral sclerosis (ALS). Rinsho Shinkeigakku 35 (1995) 1543-1545
136. Takahashi R., Yokoji H., Misawa H., et al. A null mutation in the human CNTF gene is not causally related to neurological diseases. Nat Genet 7 (1994) 79-84
137. Orrell R., King A., Lane R., and de Belleroche J. Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis. J Neurol Sci 132 (1995) 126-128
138. Masu Y., Wolf E., Holtmann B., et al. Disruption of the CNTF gene results in motor neuron degeneration. Nature 365 (1993) 27-32
139. Al-Chalabi A., Scheffler M., Smith B., Parton M., Cudkowicz M., Andersen P., et al. CNTF genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. Ann Neurol 54 (2003) 130-134
140. Lin C., Bristol L., Jin L., Dykes-Hoberg M., Crawford T., Clawson L., et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20 (1998) 589-602
141. Trotti D., Rolfs A., Danbolt N., Brown R., and Hediger M. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 2 (1999) 427-433
142. Meyer T., Albert B., Roemer K., Martin T., Kalscheuer V., Gottert E., et al. High rate of constitutional chromosomal rearrangements in apparently sporadic ALS. Neurology 60 (2003) 1348-1350